Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Clesrovimab · Enflonsia, MK-1654

Monoclonal antibody · Antagonist of respiratory syncytial virus F protein · developed by Merck Sharp Dohme

Approved FDA, Jun 2025
MRK Developer

What is Clesrovimab?

Clesrovimab (ENFLONSIA) is a monoclonal antibody that binds the respiratory syncytial virus (RSV) F protein and inhibits viral fusion. It is studied in RSV infection, including prevention of RSV lower respiratory tract disease in neonates and infants.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Enflonsia, MK-1654
Drug type
Monoclonal antibody
Targets
respiratory syncytial virus F protein
Mechanism
Antagonist of respiratory syncytial virus F protein
Pathways
viral fusion inhibition
Therapy area
Infectious disease
Developer
Merck Sharp Dohme (MRK)
FDA status
Approved as Enflonsia (June 9, 2025), BLA761432 · FDA label
UNII
VJO29R4CP9

✅ FDA-approved uses

From the indications section of the FDA label (version of Oct 14, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

RSV Infection

More from Merck Sharp Dohme

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Clesrovimab

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.